VCYT icon

Veracyte

29.71 USD
-1.50
4.81%
At close May 9, 4:00 PM EDT
After hours
29.65
-0.06
0.20%
1 day
-4.81%
5 days
-2.53%
1 month
-8.92%
3 months
-29.14%
6 months
-23.61%
Year to date
-26.53%
1 year
44.01%
5 years
11.90%
10 years
236.85%
 

About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Employees: 824

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,042% more call options, than puts

Call options by funds: $8.4M | Put options by funds: $736K

116% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 25

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

17% more capital invested

Capital invested by funds: $2.78B [Q3] → $3.25B (+$471M) [Q4]

8% more funds holding

Funds holding: 290 [Q3] → 314 (+24) [Q4]

0.52% more ownership

Funds ownership: 106.74% [Q3] → 107.26% (+0.52%) [Q4]

14% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 119

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$37
25%
upside
Avg. target
$42
41%
upside
High target
$45
51%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
UBS
Lu Li
25% 1-year accuracy
1 / 4 met price target
41%upside
$42
Buy
Maintained
8 May 2025
Needham
Mike Matson
35% 1-year accuracy
39 / 111 met price target
38%upside
$41
Buy
Maintained
8 May 2025
Guggenheim
Subbu Nambi
26% 1-year accuracy
6 / 23 met price target
25%upside
$37
Buy
Maintained
9 Apr 2025
Stephens & Co.
Mason Carrico
11% 1-year accuracy
3 / 27 met price target
51%upside
$45
Overweight
Reiterated
26 Mar 2025
Craig-Hallum
John Wilkin
33% 1-year accuracy
1 / 3 met price target
51%upside
$45
Buy
Initiated
20 Mar 2025

Financial journalist opinion

Based on 12 articles about VCYT published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
Positive
Zacks Investment Research
3 days ago
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Veracyte (VCYT) a New Buy Stock
Neutral
Seeking Alpha
4 days ago
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babington - Wolfe Research Tejas Savant - Morgan Stanley Thomas DeBourcy - Nephron Research Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2025 Financial Results Webcast.
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
4 days ago
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Neutral
Business Wire
4 days ago
Veracyte Announces First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” said Marc Stapley, Veracyte's chief executive officer. “With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positione.
Veracyte Announces First Quarter 2025 Financial Results
Neutral
Business Wire
2 weeks ago
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
Neutral
Business Wire
2 weeks ago
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
Neutral
Business Wire
2 weeks ago
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release
Positive
Investors Business Daily
3 weeks ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Positive
Zacks Investment Research
3 weeks ago
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Charts implemented using Lightweight Charts™